Healthy SubjectsPhase 1NCT03757390
Bioequivalence Study of CJ-30060 in Healthy Volunteers
A Phase 1 study testing Exforge® tab 5/160mg, Crestor® tab 10mg and CJ-30060 5/160/10mg in people with Healthy Subjects, run by HK inno.N Corporation at 1 site in South Korea.
Trial summary
To compare the pharmacokinetics and safety after a single dose administration of CJ-30060 and Exforge® 5/160mg, Crestor® 10mg in healthy volunteers. Read more about this study
- Who is it for?
- Ages 20 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Subjects
- What is being tested?
- Exforge® tab 5/160mg, Crestor® tab 10mg and CJ-30060 5/160/10mg
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 52 participants
- Where
- 1 siteSouth Korea
- Study dates
- 9 Nov 2018to 14 Dec 2018
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy volunteers aged 20 to 45 years at screening
- BMI: 18~29.9kg/㎡
- Body weight ≥50kg
- Subjects who decided to participate in the study and signed informed consent form voluntarily after receiving detailed explanation of the study and fully understanding
Who cannot join
- Subjects who had a medical history of severe cardiovascular, respiratory, hepatobiliary, renal, hematological, gastrointestinal, endocrinological, immunological, dermatological or neuropsychological disease
- Subjects who have symptoms of an acute disease within 28days before first administration
- Subjects who have clinically significant active, chronic disease
- Subjects who fall under the criteria below in laboratory test
- AST/ALT > UNL (upper normal limit) × 2
- Total bilirubin > UNL × 1.5
Show all 10Show fewer
- CrCL < 50mL/min
- CPK > UNL × 2.5
- Subjects with clinically significant low blood pressure at screening test(systolic blood presure is less than 100mmHg or diastolic blood pressure is less than 60mmHg)
- Subjects with any positive reaction in HBsAg, anti-HCV Ab, anti HIV Ab, VDRL tests
Trial locations and contacts
1 site in 1 country.
South Korea1 site, 1 recruiting
- Recruiting
Korea University Anam Hospital
Seoul
About this study
Official title: An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CJ-30060 in Healthy Subjects
To compare the pharmacokinetics and safety after a single dose administration of CJ-30060 and Exforge® 5/160mg, Crestor® 10mg in healthy volunteers.
Read the detailed description
The purpose of this study is to compare the pharmacokinetics and safety after a single dose administration of CJ-30060 and Exforge® 5/160mg, Crestor® 10mg in healthy volunteers.
- Conditions
- Healthy Subjects
- Being tested
- Exforge® tab 5/160mg, Crestor® tab 10mg, CJ-30060 5/160/10mg
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Exforge® tab 5/160mg, Crestor® tab 10mgDrug
co-administration of Amlodipine 5mg/Valsartan 160mg(combination drug) and Rosuvastation 10mg
CJ-30060 5/160/10mgDrug
Fixed-dose combination drug containing Amlodipine 5mg and Valsartan 160mg and Rosuvastatin 10mg
| Study group | Role | What they receive |
|---|---|---|
| Sequence 1 | Experimental | * period 1: receive Exforge® tab 5/160mg, Crestor® tab 10mg
* period 2: receive CJ-30060 5/160/10mg Receives: Drug: Exforge® tab 5/160mg, Crestor® tab 10mg; Drug: CJ-30060 5/160/10mg |
| Sequence 2 | Experimental | * period 1: receive CJ-30060 5/160/10mg
* period 2: receive Exforge® tab 5/160mg, Crestor® tab 10mg Receives: Drug: Exforge® tab 5/160mg, Crestor® tab 10mg; Drug: CJ-30060 5/160/10mg |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cmax of amlodipine
Measured: Up to 144 hours post-dose
Cmax of valsartan
Measured: Up to 48 hours post-dose
Cmax of rosuvastatin
Measured: Up to 72 hours post-dose
AUClast of amlodipine
Measured: Up to 144 hours post-dose
AUClast of valsartan
Measured: Up to 48 hours post-dose
AUClast of rosuvastatin
Measured: Up to 72 hours post-dose
Secondary outcomes (1)
AUCinf of amlodipine, valsartan, rosuvastatin
Measured: Up to 144 hours post-dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Nov 2018
- Study start9 Nov 2018
- Primary completion14 Dec 2018 (estimated)
- Study completion14 Dec 2018 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy SubjectsStudies of the same condition, open and under way.
- More trials run by HK inno.N CorporationThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 52 participants (estimated)
Sponsor and investigators
- Lead sponsor
- HK inno.N Corporation
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Ji Young Park, PhD, Principal investigator, Korea University Anam Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03757390
- Sponsor's protocol ID
- CJ_EXR_104
- Status last verified
- Nov 2018
- First submitted
- 25 Nov 2018
- Last updated
- 28 Nov 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Nov 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CJ-30060 in Healthy Subjects
- ClinicalTrials.gov ID
- NCT03757390
- Acronym / sponsor ID
- CJ_EXR_104
- Conditions
- Healthy Subjects
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 52 participants (estimated)
- Lead sponsor
- HK inno.N CorporationIndustry (pharma, biotech, devices)
- Study start
- 9 Nov 2018 (actual)
- Primary completion
- 14 Dec 2018 (estimated)
- Study completion
- 14 Dec 2018 (estimated)
- First posted
- 28 Nov 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To compare the pharmacokinetics and safety after a single dose administration of CJ-30060 and Exforge® 5/160mg, Crestor® 10mg in healthy volunteers.
Detailed description
The purpose of this study is to compare the pharmacokinetics and safety after a single dose administration of CJ-30060 and Exforge® 5/160mg, Crestor® 10mg in healthy volunteers.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Sequence 1 | Experimental | Drug: Exforge® tab 5/160mg, Crestor® tab 10mg, Drug: CJ-30060 5/160/10mg* period 1: receive Exforge® tab 5/160mg, Crestor® tab 10mg * period 2: receive CJ-30060 5/160/10mg |
| Sequence 2 | Experimental | Drug: Exforge® tab 5/160mg, Crestor® tab 10mg, Drug: CJ-30060 5/160/10mg* period 1: receive CJ-30060 5/160/10mg * period 2: receive Exforge® tab 5/160mg, Crestor® tab 10mg |
Who may qualify
- Ages
- 20 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Healthy volunteers aged 20 to 45 years at screening
- BMI: 18~29.9kg/㎡
- Body weight ≥50kg
- Subjects who decided to participate in the study and signed informed consent form voluntarily after receiving detailed explanation of the study and fully understanding
Key exclusion criteria (10 listed)
- Subjects who had a medical history of severe cardiovascular, respiratory, hepatobiliary, renal, hematological, gastrointestinal, endocrinological, immunological, dermatological or neuropsychological disease
- Subjects who have symptoms of an acute disease within 28days before first administration
- Subjects who have clinically significant active, chronic disease
- Subjects who fall under the criteria below in laboratory test
- Subjects with clinically significant low blood pressure at screening test(systolic blood presure is less than 100mmHg or diastolic blood pressure is less than 60mmHg)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Exforge® tab 5/160mg, Crestor® tab 10mgco-administration of Amlodipine 5mg/Valsartan 160mg(combination drug) and Rosuvastation 10mg | Drug | Sequence 1, Sequence 2 |
| CJ-30060 5/160/10mgFixed-dose combination drug containing Amlodipine 5mg and Valsartan 160mg and Rosuvastatin 10mg | Drug | Sequence 1, Sequence 2 |
Primary outcome
Cmax of amlodipine
Time frame: Up to 144 hours post-dose
Cmax of valsartan
Time frame: Up to 48 hours post-dose
Cmax of rosuvastatin
Time frame: Up to 72 hours post-dose
AUClast of amlodipine
Time frame: Up to 144 hours post-dose
AUClast of valsartan
Time frame: Up to 48 hours post-dose
AUClast of rosuvastatin
Time frame: Up to 72 hours post-dose
1 secondary outcome
AUCinf of amlodipine, valsartan, rosuvastatin
Time frame: Up to 144 hours post-dose
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Nov 2018.
- Individual participant dataSharing planned: No
Related trials for Healthy Subjects
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingObservational study
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
Healthy
RecruitingObservational study
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Graft-Versus-Host Disease, Graft-versus-leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ji Young Park, PhD principal investigator
Korea University Anam Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Exforge® tab 5/160mg, Crestor® tab 10mg and CJ-30060 5/160/10mg in people with Healthy Subjects, run by HK inno.N Corporation at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 28 Nov 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Hyo-Sook Seo (82-2-6477-0262, hs.seo1@cj.net), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cmax of amlodipine (time frame: Up to 144 hours post-dose). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Nov 2018.